mcp5 Antibody

What are the different types of MCP5 referred to in scientific literature?

Scientific literature references two distinct proteins as "MCP5":

• Mouse CCL12/MCP-5 (Monocyte Chemotactic Protein-5): A chemokine involved in inflammatory responses and leukocyte recruitment in mice .

• MCP5 in Borrelia burgdorferi: A methyl-accepting chemotaxis protein crucial for the Lyme disease pathogen's movement, mammalian infection, and transmission from tick vectors .

When designing experiments, it's essential to clearly identify which MCP5 you're investigating to select appropriate antibodies and controls. For mouse CCL12/MCP-5 research, several validated antibodies are available, including polyclonal (AF428) and monoclonal (MAB4281, MAB428) options .

What is the structure and function of Mouse CCL12/MCP-5?

Mouse CCL12/MCP-5 is a chemokine with the accession number Q62401, spanning amino acids Gly23-Gly104 . It functions primarily as a chemoattractant, recruiting immune cells to sites of inflammation.

Functionally, CCL12/MCP-5 exhibits chemotactic activity through binding to CCR2 receptors. This is demonstrated in experimental models where recombinant Mouse CCL12/MCP-5 chemoattracts BaF3 mouse pro-B cells transfected with human CCR2A in a dose-dependent manner . This chemotactic activity can be neutralized by specific antibodies, making these tools valuable for studying CCL12/MCP-5 function in inflammatory responses.

How does MCP5 in Borrelia burgdorferi contribute to pathogenesis?

MCP5 in B. burgdorferi serves as a methyl-accepting chemotaxis protein critical for the spirochete's survival cycle. Research indicates that MCP5 is differentially expressed in response to environmental signals and at different stages of the pathogen's enzootic cycle .

The expression of mcp5 is regulated by two key pathways: the Hk1-Rrp1 pathway and the Rrp2-RpoN-RpoS pathway, which are essential for the spirochete's colonization of tick vectors and mammalian hosts, respectively . Infection experiments with mcp5 mutants have demonstrated that spirochetes lacking MCP5 cannot establish infections in either immunocompetent C3H/HeN mice or SCID mice with defective adaptive immunity . This indicates that MCP5 plays a crucial role in helping B. burgdorferi evade host innate immunity.

What applications are recommended for different types of MCP5 antibodies?

Different MCP5 antibodies have specific applications based on their characteristics:

When selecting an antibody, consider your experimental design, required sensitivity, and specific application. For neutralization assays, monoclonal antibodies MAB4281 and MAB428 demonstrate high efficacy, while the polyclonal antibody PAC075Mu01 offers versatility across multiple applications .

How can I validate the specificity of an MCP5 antibody?

Validating antibody specificity is crucial for experimental rigor. For MCP5 antibodies, consider these methodological approaches:

• Western blot against recombinant MCP5: Compare detection of purified recombinant MCP5 (like catalog #428-P5) versus other chemokines to confirm specificity .

• Knockdown/knockout controls: Test the antibody in tissues/cells with confirmed MCP5 deletion or knockdown. For B. burgdorferi MCP5, an mcp5 mutant strain has been developed that can serve as a negative control .

• Neutralization assay titration: For functional validation, perform a dose-response neutralization assay. Effective MCP5 antibodies should neutralize chemotaxis in a dose-dependent manner, as demonstrated with both MAB4281 and MAB428 .

• Cross-reactivity testing: Especially important when working with chemokines, which often share structural similarities. Test against closely related proteins like other MCP family members.

The reported validation for commercial antibodies shows that Mouse CCL12/MCP-5 antibodies can effectively neutralize chemotaxis in the BaF3 mouse pro-B cell line transfected with human CCR2A, confirming their functional specificity .

What are the optimal parameters for MCP5 neutralization assays?

Based on the research data, effective neutralization assays for Mouse CCL12/MCP-5 should consider these parameters:

• Chemotactic stimulus concentration:

  • 0.2 μg/mL of Recombinant Mouse CCL12/MCP-5 for antibodies AF428 and MAB4281

  • 10 ng/mL of Recombinant Mouse CCL12/MCP-5 for antibody MAB428

• Antibody concentration range:

  • For polyclonal antibody AF428: 0.8-4.0 μg/mL (ND50)

  • For monoclonal antibodies MAB4281 and MAB428: 0.5-2.5 μg/mL (ND50)

• Cell model: BaF3 mouse pro-B cell line transfected with human CCR2A provides a responsive system for measuring chemotaxis .

• Detection method: Resazurin (Catalog # AR002) can be used to measure cell migration quantitatively .

• Expected efficacy: While antibodies like MAB4281 show high neutralization capacity, note that MAB428 achieves maximum neutralization of approximately 80% , indicating that complete inhibition may not always be achievable.

What storage conditions maximize MCP5 antibody stability?

Proper storage is essential for maintaining antibody functionality. For MCP5 antibodies:

• Long-term storage: Store at -20°C for up to 24 months. Aliquoting is recommended to avoid repeated freeze/thaw cycles .

• Frequent use: Store at 4°C for convenience when using regularly .

• Storage buffer: MCP5 antibodies are typically formulated in PBS pH 7.4, containing 0.02% NaN3 and 50% glycerol to enhance stability .

• Stability testing: Quality antibodies undergo accelerated thermal degradation testing (e.g., 37°C for 48h) to ensure stability, with acceptable loss rates below 5% within the expiration date .

• Handling: Avoid repeated freeze/thaw cycles, which can lead to protein denaturation and reduced functionality .

When receiving a new antibody, consider creating small working aliquots to minimize freeze/thaw cycles of your stock solution.

How should I determine the optimal dilution of MCP5 antibody for my application?

Determining optimal antibody dilution is application-specific and requires empirical testing:

• Start with manufacturer recommendations:

  • Western blot: 0.01-2μg/mL for polyclonal antibodies

  • Immunohistochemistry/Immunocytochemistry: 5-20μg/mL

  • Neutralization assays: 0.5-4.0 μg/mL range depending on the specific antibody

• Perform a dilution series: Test a range of concentrations spanning at least one order of magnitude above and below the recommended concentration.

• Include positive and negative controls: Use tissues or cells known to express or lack MCP5, respectively.

• For functional assays: Create a dose-response curve similar to those shown in the scientific data for neutralization assays .

• Validation approach: "Optimal dilutions should be determined by each laboratory for each application," as noted in multiple antibody protocols .

A systematic optimization approach ensures both specificity and efficiency in antibody usage while minimizing background.

How is MCP5 expression regulated in different biological contexts?

Understanding MCP5 regulation provides insights into its biological function:

For B. burgdorferi MCP5:

• Dual regulation system: Expression of mcp5 is controlled by both the Hk1-Rrp1 and Rrp2-RpoN-RpoS pathways .

• Host-dependent expression: mcp5 expression shows significantly higher levels in mammalian hosts compared to ticks or in vitro conditions .

• Tissue-specific variation: Within mammalian hosts, mcp5 expression is particularly elevated in heart tissues at 1 and 3 months post-infection compared to other tissues .

• Temporal dynamics: Expression levels change during different stages of the pathogen's enzootic cycle .

• Environmental responsiveness: mcp5 expression responds to environmental signals, helping B. burgdorferi adapt to different host environments .

This complex regulation enables the bacterium to adapt to different microenvironments during its life cycle and may explain why MCP5 is crucial for both immune evasion and transmission.

What is the role of MCP5 in host-pathogen interactions during Lyme disease?

B. burgdorferi MCP5 plays several critical roles in the pathogen's life cycle:

• Mammalian infection: MCP5 is essential for establishing infection in mammalian hosts. Experiments with mcp5 mutants showed they could not establish infections in either immunocompetent (C3H/HeN) mice or SCID mice .

• Innate immune evasion: The finding that mcp5 mutants could establish infection in NSG mice (deficient in both adaptive and most innate immune responses) but not in SCID mice (deficient only in adaptive immunity) suggests MCP5 is specifically involved in evading host innate immune responses .

• Vector-to-host transmission: While mcp5 mutants could survive in feeding ticks, they failed to transmit to mice, indicating MCP5's importance in the transmission phase of the Lyme disease cycle .

• Motility and chemotaxis: As a methyl-accepting chemotaxis protein, MCP5 likely plays a role in directing the spirochete's movement in response to environmental cues, which is crucial for tissue invasion and dissemination .

These findings highlight MCP5 as a potential target for intervention strategies aimed at disrupting the B. burgdorferi life cycle.

What controls should I include when using MCP5 antibodies in experimental systems?

Robust controls are essential for interpreting MCP5 antibody experiments:

• Positive biological controls:

  • For mouse CCL12/MCP-5: Tissues known to express MCP5, such as heart tissues where expression has been documented

  • For functional assays: BaF3 cells transfected with CCR2A responding to recombinant MCP5

• Negative controls:

  • Isotype controls: Matched irrelevant antibody of the same isotype and concentration

  • For B. burgdorferi studies: mcp5 mutant strains as described in the literature

  • Blocking peptide controls: Pre-incubation of antibody with excess target antigen

• Technical controls:

  • Concentration gradient of primary antibody

  • Secondary antibody-only controls to assess non-specific binding

  • For neutralization assays: dose-response curves for both the chemokine and neutralizing antibody

• Genetic controls:

  • When possible, use knockout/knockdown models or compare wild-type, mutant, and complemented strains as described for B. burgdorferi MCP5

• Specificity controls:

  • Test cross-reactivity with related chemokines or proteins

  • When validating mutants, confirm specificity of gene deletion by checking expression of adjacent genes (e.g., confirming deletion of mcp5 did not affect mcp4 expression)

Why might I observe variable efficacy in MCP5 neutralization assays?

Several factors can contribute to variability in neutralization efficacy:

• Maximum neutralization ceiling: Even optimized antibodies like MAB428 typically achieve around 80% maximum neutralization rather than complete inhibition .

• Antibody type differences: Different antibodies have varying neutralization potencies, with ND50 values ranging from:

  • 0.8-4.0 μg/mL for polyclonal antibody AF428

  • 0.5-2.5 μg/mL for monoclonal antibodies MAB4281 and MAB428

• Recombinant protein concentration: Different optimal antibody concentrations are required depending on the amount of chemokine:

  • 0.2 μg/mL recombinant protein for some assays

  • 10 ng/mL recombinant protein for others

• Cell responsiveness: The sensitivity of the reporter cell line (e.g., BaF3 cells transfected with CCR2A) may change over passages.

• Detection method sensitivity: Ensure that the Resazurin or alternative detection method is working optimally and within its linear range .

When troubleshooting, systematically evaluate these factors and include proper controls to identify the source of variability.